WISELEAF SCIENTIFIC VENTURES



CHAPTER-1
FEMALE-SPECIFIC CLINICAL PHARMACOLOGY: HORMONAL PHYSIOLOGY, PHARMACOKINETIC VARIABILITY AND DRUG RESPONSE

Dr Pooja M[1*], Dr Renee Lynn Rego[2].

1. Assistant Professor, Department of Pharmacology, Father Muller Medical College, Mangaluru.
2. Junior Research Fellow/Clinical Research Coordinator, Department Of Clinical Research, Father Muller Medical College Hospital, Mangalore

Email Id- 1. rpoojam@gmail.com , 2. reneelynnrego@gmail.com

ORCID- 1. 0009-0009-6818-5455, 2. 0009-0006-7740-1699

Abstract

The subjunctive stage of feminine clinical pharmacology studies the various processes and phenomena regarding the interactions of hormonal physiology, variability in pharmacokinetics, and variations in pharmacodynamics on the process of medications safety and treatment efficiency in women in particular. During such processes as menstruation, pregnancy, breastfeeding, and menopause, the organism functions differently leading to the changes in drug absorption, spreading, conversion, and elimination processes. It is common practice that estrogen and progesterone levels vary creating the hormone physiologic activity, which affects the liver cytochrome P450 enzymes, passage of drugs through blood membrane, and processes in the stomach that influence an organism in general. The exact influence of variations in the physicochemical composition of female's work can be evaluated expecting the whole series of various processes. In this chapter, we will analyze the sex-specific influence on drug metabolism and efficacy process. This chapter relates to the topic under consideration of the processes of drug metabolism and their consequences for women in accordance with various hormones levels according to menstrual cycle and other factors.

Keywords: Cytochrome P450, Drug metabolism, Female hormones, Pharmacokinetics, Sex-specific pharmacology

1. Introduction

Clinical pharmacology helps one understand how drugs affect the human body, which encompasses the various processes of drug absorption, distribution, metabolism, excretion, and response. Traditionally speaking, drug development and clinical studies have either omitted women or failed to consider their specific physiological differences. However, as more evidence shows, sex-based biological differences can affect the processes of pharmacokinetics and pharmacodynamics of different substances leading to different therapeutic outcomes based on sex (effectiveness and safety profile, dosage as well as the reactions to the drug). Thus, it is necessary to recognize those distinctions in order to create safer and more efficient treatment for women.

Female-specific clinical pharmacology refers to an exclusive area of study in pharmacology that deals with the effect of physiology, sex hormones, genetics, and life transitions on drug action and effectiveness. Differences in body composition, digestive physiology, plasma proteins, liver enzyme activity, kidneys, and proteins involved in drug transportation can create differences in drug absorption, distribution, and effectiveness between males and females. Furthermore, changes in the level of estrogen, progesterone, and other hormones can change the mechanisms of metabolism, sensitivity to drugs, and metabolism itself, resulting in the variation within the pharmacological effects of certain medications. However, it should be noted that there are unequal degrees of influence on different drugs, thus sex cannot be the only factor which predetermines how effectively a certain person will respond to treatment [1].

The changes in hormonal levels through the menstrual phase must be understood in interpreting the pharmacology in women. The concentrations of estrogen and progesterone impact various activities in the body such as gastrointestinal activity and distribution of water in the body, function of drug metabolizing enzymes in the liver, and functions within the kidney. These changes may have a great impact on drugs with low therapeutic indices, drugs that rely on hormonal activities in their action, and those that may be affected by a specific process of metabolism by some enzymes. Hormonal changes that occur during the ages of maturity,

pregnancy, the postpartum period, as well as around menopause can also influence the drug pharmacokinetics and create specific needs for treatment. The case of pregnancy is particularly interesting since the physiological changes can result in essential changes in the drug distribution in the body thus influencing the drug effectiveness. Also, the drug should be assessed in relation to its impact on the baby [2].

Another critical aspect of female pharmacology is the occurrence of gender-specific differences in adverse drug reactions. Women may suffer instances of side effects of drugs with varying frequency or manifestation due to the differences in the exposure to drugs, the immense physiological features, hormonal status, comorbidity and drug use. For instance, the differences in cardiac electrophysiology may lead to the variations in the susceptibility of the individual to drug-induced QT prolongation which is accounted as well by the differences in drug metabolism and body composition. Such observations make it possible to conclude that it is very important to assess drug safety in women and to avoid chances that the dosing recommendations established in the research mostly conducted among men will work for all populations.

Innovations in pharmacogenomics, monitoring pharmacotherapy effect, physiologically-based pharmacokinetics, and precise medicine are introducing new possibilities for improving pharmacotherapy in women. Pharmacogenomics testing can help detect changes in drug-processing enzymes while physiologically-based pharmacokinetics gives an opportunity to obtain information about drug processing under various conditions by applying biological parameters and hormonal changes. An effective combination of these technologies with patient-reported information, description of reproductive health, laboratory indications, and goals of therapy will result in more targeted pharmacotherapy [3].

However, many important issues still remain unsolved that relate to menstrual cycle-related hormonal fluctuations on the effect of drugs, insufficiency of females in clinical trials, and development of scientifically-based sex-specific dosing recommendations. Also, biological sex, gender-associated aspects, age, genetics, environmental impact and illness specifics affect treatment results. Hence, female clinical pharmacology should make use of an integrated

approach that relies on understanding both traditional clinical differences and recently appeared theories while taking into account a high degree of variability in each female patient.

In this section, the physiological and hormonal basis of clinical pharmacology is reviewed from the woman's perspective. The specific aspects of pharmacokinetic changes in the menstrual cycle, transforming enzymes and interceding substances, variability of drugs' action, adverse drug responses, and pharmacogenomics are analyzed. The role of personalized dosing and pharmacotherapy is discussed in ensuring medication safety and therapeutic efficacy across various stages of reproduction [4]. The purpose of this section is to join pharmacological knowledge that is currently known with the popularization of precision medicine approaches and thus indicate the importance of using evidence-based and patient-centered methods for treatment taking into account the differences in the effect of drugs on women.

2. Female Physiology and Pharmacology

In the context of medication absorption, distribution, metabolism, and elimination, women's physiology has been noted to be important. The composition of the body, reproductive hormones, organ functioning, and activity of enzymes can cause the observed differences in the effectiveness of medications in women and men. Of equal importance is knowing how hormonal changes during the menstrual cycle, as well as the physiological state of women during pregnancy and menopause, affect the response of women to medications [5].

2.1 Physiological and Anatomical Differences

Men and women differ in many of their physiological and anatomical attributes, such as body weight, body composition and proportion of body water, fat distribution and size of organs. In general, women have a higher percentage of fat and lower percentage of water in their bodies than men. These differences can impact the distribution of lipid-soluble medications and water-soluble drugs. Gastrointestinal parameters, such as gastric emptying time, intestinal motility and gastrointestinal pH, affect the absorption of orally administered drugs. Moreover, there are noticeable differences in the binding of drugs to plasma proteins, and distribution of drugs in tissues due to different values of tissue perfusion. Finally, the pharmacokinetics of some drugs can be affected by liver metabolism and kidney function. All abovementioned processes can be influenced by age, size, hormonal status of a patient and the presence of other diseases. This

knowledge helps a physician determine the specific medication dose required by the patient; however, the dose adjustments must be based on the pharmacological data for the drug and individual characteristics of the case rather than sex of the patient [6].

2.2 Endocrine Regulation and Reproductive Hormones

The endocrine system regulates female reproduction and affects various physiological processes associated with the pharmacological reaction. The hypothalamic-pituitary-ovarian axis plays an important role in this process. The hypothalamus produces gonadotropin-releasing hormone (GnRH) which stimulates the anterior pituitary gland to produce follicle-stimulating hormone (FSH) and luteinizing hormone (LH) (**Table 1)**. The hormones are responsible for the development of ovarian follicles, ovulation, and production of estrogen and progesterone. Estrogens involve in the bone metabolism, cardiovascular work, lipid metabolism, and protein synthesis in the liver. They can also affect some drug-metabolizing enzymes and transporters, which lead to the changes in drug pharmacokinetics. Progesterone is another important hormone, which regulates the functions of reproductive system and affects the activity of smooth muscles, thermoregulation, and gastrointestinal functions. Changes in either of the hormones can lead to the changes in drug response. The significance of these changes lies in the kind of medication. Some other hormones such as thyroid hormones, cortisol, and insulin can also affect physiological processes relevant to pharmacotherapy. Hormone profile changes during puberty, pregnancy, postpartum period, pre-menopause, and menopause. The changes may affect the pharmacokinetics of medicines [7].

Table 1. Major Female Reproductive Hormones and Their Physiological and Pharmacological Functions

Hormone	Main site of production	Major physiological functions	Pharmacological significance
Estrogen	Ovaries, placenta	Regulates reproductive development,	Influences drug-metabolizing enzymes,

		menstrual cycle and bone health	transporters and receptor activity
Progesterone	Corpus luteum, placenta	Prepares the uterus for pregnancy and supports pregnancy	May influence drug metabolism and physiological responses
Follicle-stimulating hormone (FSH)	Anterior pituitary gland	Stimulates ovarian follicle development	Regulates ovarian activity and reproductive hormone production
Luteinizing hormone (LH)	Anterior pituitary gland	Triggers ovulation and supports corpus luteum formation	Influences ovarian steroid hormone production
Prolactin	Anterior pituitary gland	Stimulates milk production	Can influence reproductive endocrine function and medication considerations during lactation
Oxytocin	Produced in hypothalamus; released by posterior pituitary	Promotes uterine contractions and milk ejection	Used clinically to induce or strengthen uterine contractions

2.3 Sex-Related Differences in Drug Disposition

Drug disposition refers to the four processes of drug absorption, distribution, metabolism, and excretion (ADME) as well as pharmacokinetics of drug action. Sex differences in anatomy and physiology, hormonal activity, enzymatic processes, as well as renal function play a role in drug disposition; however, the impact of such differences across medications and patients may differ.

Drug absorption concerns gastric emptying, intestinal motility, gastrointestinal pH, and intestinal enzyme function and affects the efficiency and extent of absorption. Fluctuations in hormone levels may influence the course of some stomach processes and may alter the drug absorption.

Drug distribution highlights the differences in body composition, total body water percentage, fat distribution, and plasma protein binding, which can affect the drug distribution values.

Drug metabolism usually refers to the cytochrome P450 (CYP) system metabolism process and Phase II process. In terms of sex, variations in hormonal influence as well as sex differences could influence the pathways to medication metabolism.

Drug excretion Through the processes of glomerular filtration, tubular secretion, and tubular reabsorption, renal elimination of drugs and their active ingredients takes place. The speed of the clearance of drugs often depends on the kidney function and a physiological condition of an individual. It is worth noting that the increase in the glomerular filtration rate during pregnancy can lead to a sped-up elimination of certain drugs.

The above-mentioned differences could be significant for medicines with a narrow therapeutic window or with a high risk of adverse side effects. The assessment of the kidneys and liver functions, the assessment of the therapeutic response, and the drug monitoring when required may be beneficial for the optimization of the treatment. Thus, the consideration of the biological factors and hormonal status of a patient along with clinical evidence can ensure safer and more effective medication for women [8].

3. Hormonal Influence on Pharmacological Response

Reproductive hormones play an important role in many physiological processes that influence drug therapy. In this regard, estrogen and progesterone are critical for cellular signaling, receptor expression, enzyme activity, and tissue function. Fluctuations in the levels of these hormones over the menstrual cycle and the reproductive life stages of women may therefore have implications for drug response and metabolism. Nevertheless, the impacts of hormones on the medication will differ from one drug to another and depend on the condition of the hormones in the body of the patient, the characteristics of the physiology of the individual, and on the state of health of the patient [9].

3.1 Estrogen and Progesterone in Drug Response

Estrogen and progesterone are important in managing physiological functions that affect pharmacological reaction. The estrogen hormone controls blood circulation activity, the metabolism of bone, hepatic protein establishment, and some aspects of drug metabolism. Furthermore, estrogen can also modify the levels of some receptors and transfer proteins, hence affecting drugs acting on certain biological targets. As for the progesterone hormone, it is responsible for reproductive processes, activity of smooth muscles, thermoregulation, and activity of the central nervous system (**Figure 1)**. Changes in the concentration of progesterone can influence the effectiveness of some neurotherapeutic and hormonal treatments. The fluctuations of estrogen and progesterone hormones during menstrual cycle can also play a role in producing changes in drug action, even though not all medications undergo the same regular significant influence on their action. Realization of the influence of interactions of these hormones with the pharmacological pathways can shed light on variability of the effectiveness of the treatments among the patients. So, in case it has significance for the clinical practice, hormonal status has to be taken into account [10].



Figure 1. Schematic representation of female hormonal regulation through the hypothalamic–pituitary–ovarian (HPO) axis and its role in menstrual-cycle regulation.

3.2 Hormonal Regulation of Drug Receptors and Signaling

Hormonal activity has an impact on drug responses through alterations in receptor presence, receptor reactivity, intracellular message-transmitting mechanisms, and gene activation processes. Estrogens operate via estrogen-specific substances such as ERα and Eα that enable the transmission of controlled information about hormonal action to particular genes responsible for cell growth and development and metabolic activity. Studies suggest that such interactions can lead to changes in the pharmacological activities of certain medications. In its turn, progesterone acts via its specific receptor and induces expressions of certain genes and cellular reactions in reproductive organs and other body parts (**Figure 2)**. Hormonal activity can also interfere with neuronal systems, for example, with gamma-aminobutyric acid (GABA) and glutamate pathways that are significant for brain activity. Such effects may lead to the differences in the influence of various neuroactive medications on people's organisms. It should be noted that regulated activity of all types of receptors does not allow scientists to foresee the effects of medications in terms of their efficacy. This is due to the different types of distribution of receptors in the organism, variation of hormones in circulation, differences in the structure of tissues, and peculiarities of certain medications' action mode [11].

3.3 Hormonal Changes Across Different Life Stages

Hormones are released across a woman's lifespan and influence the response of medication when given at different ages. Estrogen and progesterone rising during puberty contribute to reproductive maturity and changes in body composition at this age. The changes in physiology may influence drug distribution within the body as it may change the treatment options. The changes occurring during pregnancy are significant as they transport hormones and modify physiology in many ways. An increase in plasma volume, shifts in protein concentrations, and renal processes change pharmacokinetics of drug in the body and require reassessment of the medication we take. Hormonal levels change greatly during the postpartum which means that hormone levels must be reevaluated. Lactation processes add new meanings and considerations regarding drugs entering the breast milk. Also, perimenopausal and menopausal stages are those when ovarian hormone production declines which may influence conditions associated

with bone, cardiovascular system, sleep, body composition, and health conditions associated with hormones [12].



Figure 2 Hormonal Regulation of Drug Receptors and Signaling Pathways

4. Menstrual-Cycle-Related Pharmacokinetic Changes

Changes in hormone levels lead to a synchronized hormonal cycle that involves the regulation of fertility/menstruation and also may have an impact on selected pharmacokinetics processes. Estrogen and progesterone may affect gastrointestinal function, the balance of body fluids and several metabolic pathways. Such changes in the physiology of one's body may lead to the differences in drug absorption and distribution, metabolism and excretion. The extent of the effect will be different from person to person and drug to drug and not all observed hormonal changes will lead to clinically significant alterations in pharmacokinetics [13].

4.1 Phases of the Menstrual Cycle and Hormonal Fluctuations

The menstrual cycle undergoes four stages: menstruation, follicular, ovulatory, and luteal phases. The first stage signifies the dropping levels of progesterone and estrogen, hence the

detachment of the lining of the uterus. In the second stage, follicle-stimulating hormone (FSH) helps the ovarian follicles to grow. The stimulation of the luteinizing hormone (LH) results in the ovulation process when the mature egg is released from one of the ovaries. The process of the luteal phase features the secretion of estrogen and progesterone by the corpus luteum, which prepares the endometrium for a possible implantation of the fertilized ovum. The cycles of hormone release can affect physiological processes important for pharmacology such as the motion of intestines, fluid balance, and the functioning of drug metabolic activity. The changes can influence the drug absorption and distribution, metabolism, and excretion. However, variations in pharmacokinetics of the menstrual cycle are not constant for all drugs and depend on the properties of the drug, the degree of sensitivity, and individual physiological characteristics [14].

4.2 Effects on Drug Absorption and Distribution

Fluctuation of hormones through the menstrual cycle can have an effect on gastrointestinal motility and fluid regulation and may affect drug absorption and distribution. Progesterone may have an effect on smooth muscle activity while estrogen fluctuations may affect fluid balance and other processes. This hormonal fluctuation could be a factor in the differences in absorption of certain oral drugs, but data on its real effect on the significant clinical outcomes is still sparse. Drug distribution depends on plasma volume, total body water, body composition, and protein binding. The fluid retention characteristic of the menstrual cycle probably causes insignificant changes in the body weight and fluid distribution and consequently has its influence on drugs sensitive to body-fluid compartments (**Table 2)**. Moreover, fluctuations in physiological conditions can have an impact on drug availability in tissues. However, the actions are not the same across different subjects as well as for various medications. Hence, it is important to understand the influence of hormones on absorption and distribution on the example of sex differences in pharmacokinetics. Still, no stimulation is necessary for dose adjustments even if it is menstruation [15].

Table 2. Pharmacokinetic Changes During Different Phases of the Menstrual Cycle

Menstrual cycle phase	Hormonal changes	Physiological changes	Potential pharmacokinetic effects

Menstrual phase	Estrogen and progesterone levels are low	Shedding of the uterine lining	Hormonal changes may influence gastrointestinal function
Follicular phase	Estrogen gradually increases	Follicular development and changes in reproductive hormone levels	Possible changes in gastrointestinal motility and drug absorption
Ovulatory phase	Estrogen peaks before ovulation; LH surge occurs	Ovulation takes place	Hormonal fluctuations may influence fluid balance and drug distribution
Luteal phase	Progesterone increases; estrogen shows a secondary rise	Increased basal body temperature and changes in fluid regulation	Changes in gastrointestinal motility and body-fluid distribution may affect drug disposition

4.3 Changes in Drug Metabolism and Excretion

Both estrogen and progesterone can affect some of the enzymes responsible for drug metabolism along with some of the physiological processes related to drug removal. There have been studies of the potential influence of changes in hormone concentrations on activities of cytochrome P450 (CYP) enzymes and other systems of metabolism. However, the effect may vary depending on the effect of the specific enzyme and medication. Also, it has not proven that all drug pathways experience changes associated with the hormonal activities of the menstrual cycle. The processes responsible for the removal of medications through urine can be grouped into renal blood circulation, glomerular filtration, tubular secretion and tubular reabsorption. Although hormones can affect fluid regulation and some of the functions of the renal system, there has not been significant evidence that menstruation is associated with clinically relevant changes in the clearance of many drugs. Overall, it is essential to take into

account the possibility of differences in drug metabolism processes, especially when dealing with drugs that can be characterized as having a small therapeutic range and high pharmacokinetic variability. However, the choice of the treatment process should be based more on the pharmacological evidence regarding the treatment and clinical data [16].

5. Hormonal Influence on Drug Metabolism

Hormones play a significant role in drug metabolism, impacting the activity and expression of enzymes that perform drug biotransformation. Throughout the body, estrogen, progesterone, and different hormones can affect activity of hepatic enzymes and concentration of certain plasma proteins involved in drug clearance. Such hormonal activities change drug absorption, distribution, metabolism, and elimination process and thus change the therapeutic effectiveness of the drugs and their abuse potential. Hormones also play a role in the creation of active and inactive metabolites. The effects of the hormones depend on the specific hormone, drug, metabolic pathway, as well as on the current hormonal status and other individual clinical characteristics of the person receiving medications [17].

5.1 Hormonal Regulation of Hepatic Enzyme Activity

The liver is considered as the main organ responsible for converting a large number of drugs. Hepatic drug metabolism involves phase I and phase II processes. Phase I processes include hydrolysis, oxidation, and reduction. Phase II processes include glucuronidation and sulfation processes. A significant contribution to drug metabolism is made by cytochrome P450 enzymes with CYP2D6, CYP3A4, and CYP2C9 being some of the most common. Differences in the level of activity shown by some of the hepatic enzymes have also been reported with regard to gender, but the findings differ from enzyme to enzyme and from one sample population to another. It has been shown that estrogen and progesterone in women can affect selected metabolic pathways by changing the way certain enzymes are produced and regulated in the body, which leads to the changes in drug metabolism. It is essential to understand that hormone effects are not the same for every CYP enzyme. Pregnancy serves as a great illustration of the influence of hormones on drug metabolism. Higher concentration of hormones and the physiological changes in the human body are essential for establishing changes in the metabolic pathways for specific drugs [18].

5.2 Effects on Renal Function and Drug Clearance

Kidneys are essential organs responsible for the removal of drugs and their metabolites via glomerular filtration, active tubular secretion, and tubular reabsorption. Different factors influence renal clearance such as renal function, renal blood flow, transporters' activity, age and physiological situation. Hormonal factors may have an indirect effect on renal function through their impact on fluid balance, blood system regulation and other physiological processes. During pregnancy, considerable changes in renal functioning occur including increased renal blood flow and glomerular filtration rate. Changes mentioned above can cause faster removal of some renally-cleared drugs from the body and therefore lower the exposure of the drug to general circulatory system. However, poor kidney function can lead to reduced drug clearances and thus increased likelihood of drug accumulation and toxicity. It is important to examine renal drug clearance by methods suitable for clinical practice and according to prescription for medication being used. The patient's hormonal state might give a useful idea on the situation but dose adjustments should depend mainly on the patient's renal functioning and clinical state as well as pharmacokinetic characteristics of each drug [19].

5.3 Clinical Implications of Hormone-Mediated Metabolic Changes

Changes in drug metabolism due to hormone action may affect drug effectiveness, duration of treatment, and chance of adverse reactions to drugs. Hormonal effects on the drugs with narrow therapeutic range are particularly significant since even minor changes in drug exposure may lead to either treatment inefficacy or intoxication. Such drugs might be different antiepileptic drugs, immunosuppressants, or anticoagulants, while clinical implications of hormonal effects are unique for every drug. Changes in physiology related to pregnancy, use of hormonal contraceptives, and menopause may have an impact on drug effects, especially relating these factors to drug interactions. In some cases, changes of enzyme activity may impact the action of drugs taken simultaneously and the formation of pharmacologically active metabolites. Clinically, patients need thorough medication reconciliation, evaluation of hepatic and renal functions, observation for side effects, and maybe therapeutic drug monitoring. When changing doses, all recommendation must be based on data obtained from scientific literature and patients' needs and not only on hormonal factors. By combining hormonal and physiological

data with genetic and clinical facts, the safest and most effective pharmacotherapy can be administered [20].

6. CYP Enzymes and Drug-Metabolizing Pathways

Drug metabolism is a key player in pharmacokinetics, thereby affecting the drug clearance, duration of action and metabolite formation. Cytochrome P450 (CYP) enzymes significantly contribute to the metabolism of many drugs. The variability of enzyme activity is due to genetic factors, age and physiological characteristics, hormonal condition and concurrent medications, which results in the difference in drug response among men and women. These differences influence the therapeutic effect as well as side effects of drugs. Therefore, it is thorough knowledge of drug metabolism and its differences based on sex is necessary to predict drug interactions, individualize treatment and improve safe medication use [21].

6.1 Overview of Cytochrome P450 Enzymes

Cytochrome P450 refers to the superfamily of heme enzymes that are mainly found in the liver and are also expressed in the intestines and other tissues. Their primary role is to participate in Phase I drug metabolism reactions, notably oxidation, the process that allows increasing the drugs' polarity thus making drug's removal easier. Some important CYP enzymes include CYP3A4, CYP2D6, CYP2C9, CYP2C19, CYP1A2. CYP3A4 is the enzyme responsible for the metabolism of many drugs, such as some statins, immunosuppressants, and calcium-channel blockers. CYP2D6 is important for the metabolism of some medicines, including some antidepressants and antipsychotic drugs. CYP2C9 enzyme helps with the metabolism of warfarin and CYP1A2 metabolizes caffeine and some other psychiatric medications. The activity of these enzymes depends on genetics, liver function, environmental factors, diet, and inducers and inhibitors of these enzymes which means that the differences in activity level in CYP may lead to different overall exposure to the drug and effectiveness of treatment. Knowing about these metabolic pathways should help doctors understand if there are any possible interactions and choose appropriate treatments [22].

6.2 Sex-Related Differences in CYP Enzyme Activity

Variations in CYP enzyme function based on sex may explain differences observed in drug metabolism. Studies on differences in some CYP strains between men and women exist.

However, results based on sex vary by specific enzyme, group being studied, and type of drug administered. For example, studies show that CYP3A activity being carried out can differ between men and women groups. This may lead to differences in drug clearance for many drugs broken down by the CYP3A strain. The CYP1A2 strain has also been studied with regards to differences noticed in certain people studies mean, smoking levels, diet and others could lead to activity differences. Estrogen can influence selected metabolism processes during pregnancy and other hormonal shifts observed in people (**Table 3)**. The genetic content of interfacing individuals with CYP2D6 and CYP2C19 and others may also play role in individual differences seen in their metabolism. Thus, it is vital for clinicians to form decisions not only based on sex as an indicator but consider all possible factors influencing activity of certain enzymes in question [23].

Table 3. Major CYP450 Enzymes, Their Substrates and Clinical Significance

CYP enzyme	Examples of drug substrates	Main metabolic function	Clinical significance
CYP3A4	Midazolam, cyclosporine, certain statins	Metabolizes a wide range of medications	Changes in enzyme activity can alter drug exposure and toxicity
CYP2D6	Metoprolol, codeine, tamoxifen	Metabolizes several cardiovascular and other drugs	Genetic variations can cause differences in drug response
CYP2C9	Warfarin, phenytoin, ibuprofen	Metabolizes anticoagulants and other medications	Reduced activity may increase drug exposure and adverse effects
CYP1A2	Caffeine, theophylline, clozapine	Metabolizes several centrally acting drugs	Activity can be influenced by smoking, medications and hormonal factors

CYP2C19	Omeprazole, clopidogrel, diazepam	Metabolizes proton-pump inhibitors and other drugs	Genetic differences can influence therapeutic effectiveness
CYP2E1	Paracetamol (minor pathway), ethanol	Metabolizes certain small molecules and contributes to toxic metabolite formation	Increased activity can contribute to drug-related toxicity under certain conditions

6.3 Phase I and Phase II Drug-Metabolizing Pathways

Drug metabolism typically comprises two phases: phase I and phase II metabolism. Both phases may happen together or separately based on the chemical properties of the drug (**Figure 3)**.

Phase I metabolism includes such processes as oxidation, reduction, and hydrolysis, wherein some functional groups are added onto or uncovered within the molecule of the drug. Phase I metabolism is mainly carried out by the cytochrome P450 enzymes. These metabolic reactions can lead either to the formation of inactive metabolites, active metabolites possessing pharmacodynamics characteristics, or intermediates, which are then charged with some specificity.

Phase II metabolism involves the conjugation of the drug or its metabolite with some endogenous natural compounds, which usually increases its water solubility. The important phase II metabolic pathways include glucuronidation (the process of the glucuronidation catalyzed by the udp-glucuronosyltransferases), sulfation process (the process of sulfation catalyzed by sulfotransferases), and acetylation catalyzed by the N-acetyltransferases (NAT). The metabolic pathways can be influenced by the presence of particular hormones, genetics, age, or some physiological processes. One of the examples is pregnancy that can lead to some changes in the activity of some metabolic enzymes [24].



Figure 3 Phase I and Phase II Drug Metabolism Pathways

6.4 Clinical Significance of Enzyme-Mediated Drug Interactions

Drug interactions as a result of enzymatic processes take place when the action of one drug may affect the metabolism of another drug. During the process of enzymatic inhibition, the metabolism of a drug may be lowered, leading to increased drug concentration. On the contrary, incorporation of drug enzymes into metabolism (enzymatic induction) may mean reduced concentration of drug, adversely affecting therapeutic potential. As an example, CYP3A4 may serve as an enzyme being inhibited, which may lead to increased concentration of sensitive substrates. As far as the enzyme inducers concerned, using rifampicin may help reduce the concentration of CYP3A4 substrates in the body. The outcome is highly dependent on the kinds of drugs affected, severity of the interaction, and whether active or toxic products are formed through metabolism. Besides, contraceptive hormonal preparations may also induce significant drug interactions. In particular, considering the case of those drugs which induce enzymes, such

medications can reduce the activity of hormonal contraceptives. On the other hand, certain hormonal medications may influence the metabolism of the drugs taken at the same time. In order to manage drug interactions, doctors should look through the medications taken by patients and investigate certain metabolic pathways [25].

7. Drug Transporters

The membranes of cells consist of molecules known as drug transporters. Therefore, they carry drugs as well as other molecules that occur naturally to or through a cell membrane thereby changing drug absorption, distribution, penetration within tissues as well as elimination. The process whereby a drug is allowed to enter or leave a cell or an organ is performed by transporters hence affecting total drug exposure in the system. Variations in functions or expressions of drug transporter may lead toalterations in drug concentrations as well as change how effective a given drug would be thus affecting chances of adverse drug reactions. Genetic make-up, body conditions and hormonal control can also lead to different activities of drug transporters [26].

7.1 Major Drug Transporters and Their Functions

Transporters of drugs are two major types which are influx and efflux transporters. Influx transporters allow substances enter into cells, while efflux transporters export drugs or metabolites from cells. Both categories are involved in drug disposition. Organic anion transporting polypeptides (OATPs) help in taking in specific groups of drugs, as well as endogen high molecular products. Organic anion transporters (OATs) and organic cation transporters (OCTs) are involved in the process of drugs in the kidneys. P-glycoprotein (P-gp), which is also referred to as ABCB1, is a type of efflux transporter which prevents drugs from getting accumulated in cells. It can be found in intestines, liver, kidneys, and blood-brain barrier. Breast cancer resistance protein (BCRP or ABCG2) is another efficacious transporter which is engaged in import/export of drugs. Multidrug resistance proteins (MRPs) are responsible for the process of transporting substances out of the body. Changes in systems of transporters can result in the trouble of drug availability, renal clearance, and tissue delivery. Thus, it helps define why the analysis of transporter activity is important in medicine [27].

7.2 Hormonal Regulation of Drug Transporters

Hormones might influence the behavior of drug transporters through modulation of transcription and intracellular signalling pathways. Estrogen and progesterone have been evaluated to establish their potential role in transporters related to the uptake and efflux of drugs. These processes might contribute to the transition of certain drugs across membranes of intestines, liver, kidneys and other cells. Transporters that have great relevance with respect to this effect are P-glycoprotein and BCRP, because they impact the uptake and tissue distribution of particular drugs. The alterations in the transporter expression may change the levels of drugs entering the bloodstream and reaching a particular organ. Besides, hormonal changes in pregnancy can also have an impact on the transporter expression, along with considerable changes in the functioning of organs and blood plasma volume. Nevertheless, despite the importance of hormones on the working of transporters, their impact is complex and depends on the transporter, tissue, hormone concentration and drug. The available information confirms the importance of hormone regulation for many transporter-drug pairs, but it is still insufficient for certain combinations [28].

7.3 Effects on Drug Absorption, Distribution, and Elimination

One of the roles of drug transporters is their participation in several processes of pharmacokinetics. For example, in intestines, some efflux transporters like P-glycoprotein can send some drugs back to the intestines thus restricting drug absorption. Whereas some specific uptake transporters can help drugs move inside the intestinal cells and increase absorption here. In the liver, there are some uptake transporters that help to move some medications from the blood to hepatocytes thus either allowing their metabolism or biliary excretion. Renal transporters contribute to tubular secretion and reabsorption thus affecting the clearance of drugs and their metabolites (**Figure 4)**. At the blood-brain barrier, efflux transporters prevent certain molecules from entering the central nervous system and thus provide tissue protection. Genetic variation, diseases, influence of hormones or drugs may alter the work of transporters which can lead to a change in drug exposure and effect. Such effects play an important role in the case with drugs whose disposition depends significantly on certain transporters. Transporter

mediated interactions can be viewed together with enzyme metabolism to better understand medication interactions and make medication therapy safer [29].



Figure 4 Drug Transporters in Absorption, Distribution and Elimination

8. Pharmacodynamic Variability

Pharmacodynamics is the study that examines the connection between the concentration of a drug and its effects in the body. It encompasses processes related to the interaction of a drug with molecular targets, activation of intracellular signaling pathways, and emergence of therapeutic and/or adverse effects. Variability in pharmacodynamics can arise as a result of different receptor expression, sensitivity of the receptors, physiological properties of the individual, hormonal status, and any underlying disease. All of these above mentioned should be considered when evaluating the efficacy, safety and tolerance of drugs in a given population. Hence, patients with the same concentration of the drug can achieve different treatment outcomes. Therefore, understanding of pharmacodynamics is a very important issue in

medicine due to its importance in choosing the right medication, changing treatment course, and making pharmacotherapy of individual patients efficient [30].

8.1 Sex-Related Differences in Drug Targets and Receptor Sensitivity

Drug targets, such as receptors, enzymes, ion channels, and transport proteins, determine the action of drugs. The variation in the expression, location, or functional capabilities of these targets may explain the different pharmacological effects on both genders. Estrogens and progesterone can affect the receptor expression and cell signaling in various tissues. Estrogen receptors are responsible for gene activation and control the processes involved in cardiovascular disease, metabolism of the bones, and inflammation. The hormonal influence can also affect the receptors of the neurotransmitters or ion channels and lead to the differences in responses to certain neurological or cardiovascular drugs. For instance, the differences in the cardiac electrophysiology can influence the drug effect on prolonged QT interval. Another example can be given from the pain processing where the variability of various pain-regulating mechanisms may be the reason for the different responses to analgesics. Nevertheless, this effect relies on various biological and medical aspects and cannot be regarded as the general rule of thumb. It is important to know the differences in drug target and receptor sensitivity to understand the variation in the effectiveness of treatment. However, the choice of treatment should be based on the available medical evidence, medical characteristics [31].

8.2 Hormonal Effects on Therapeutic Efficacy

Changes in hormone levels may affect the effectiveness of treatment by changing the expression of receptors, the signaling of cells, and physiological processes, as well as some pharmacokinetic pathways. For example, estrogen and progesterone can interact with biological mechanisms of the nervous system, the cardiovascular system, metabolism, and immunology. Such interactions can contribute to the effectiveness of the treatment of certain drugs. Hormone levels can be particularly important in the treatment of diseases or disorders related to hormones or exhibiting symptoms varying according to the phases of the menstrual cycle. For instance, women can experience changes in the frequency of seizures or cases of migraine according to their menstruation cycle. Such phenomena can be linked to the interaction of reproductive hormones and neurological pathways rather than to the alteration of

drug metabolism alone. Pregnancy and menopause can alter the process of the disease and treatment. However, the importance of hormonal effects varies from one disease and one medication to another. The analysis of the symptomatology of the disease, the effectiveness of treatment, and compliance with it will help the doctor to determine if there is need in the modification of treatment [32].

8.3 Variability in Dose–Response Relationships

Stating the dose-related relationship means that the changes in either the dosage or concentration of the drug will have an impact on the intensity of the pharmacological effect. Differences in this relationship may appear due to decreased sensitivity of receptors, drug exposure to patients, biological parameters, genetics, severity of illness and use of other medications. Two subjects can take the same dose and experience different therapeutic results. Variations in the pharmacological effect of drugs are the result of different absorption and elimination of the drug from the body. Pharmacodynamic parameters of a drug can also lead to differences in reactions to drugs with similar concentrations in the body. Hormonal levels may also have a role to play in this type of variability. The goal of the process of individualized dosing is to achieve maximum therapeutic outcomes and minimal toxicity. Depending on the particular medication used, dosing may be done based on body weight biochemical parameters, body response to this medication or its monitoring. Understanding the variability of the dose-related relationship is very important for making clinical decisions in practice. By taking into account the above given aspects, the efficiency of treatment can be improved [33].

9. Sex-Specific Adverse Drug Reactions

Adverse drug reactions (ADRs), which include the unfavorable outcomes resulting from drugs' use in usual dosages, that are unexpected and harmful. Both the body composition, metabolism of drugs, the degree of their excretion by kidneys, hormonal status, and physiological conditions may serve to explain the difference in susceptibility to adverse drug reactions between men and women. The reported number of some adverse reactions suggests that the difference in question is greater for women than for men. It is vital to understand these factors in order to ensure the safety of therapy and properly monitor patients [34].

9.1 Differences in Adverse Drug Reaction Susceptibility

Variability in pharmacokinetics and pharmacodynamics may affect the risk of adverse drug reactions. Body weight, body fat ratio, volume of distribution, and metabolic activity can affect how drugs behave in the body. In some specific cases, such differences could increase the probability of the occurrence of undesirable effects due to the fact that drug dose does not take patients' established characteristics into consideration. Hormonal changes may also influence physiological responses and effects that are produced by drugs. In addition, comorbid diseases, polypharmacy, and medication use can also lead to the differences in adverse drug reaction risk. On the other hand, sex alone does not predict adverse drug reactions and susceptibility depend on many factors. Awareness of possible gender differences may allow doctors to determine which patients require closer observation, correct dose selection, and early identification of adverse effects. Moreover, ADR reporting also contributes to pharmacovigilance activities and the increase of knowledge of medication safety in women [35].

9.2 Drug-Induced Cardiac, Hepatic, and Neurological Effects

There are negative impacts of drugs that affect different organ systems, such as the cardiovascular system, liver, and central nervous system. The differences in physiological factors and exposure to the drug may have a bearing on the occurrence of side effects.

Cardiac problems: Usually women have longer QT interval as compared to men. This leads to susceptibility to drug-related QT prolongation and torsades de pointes. This category of drugs includes some antiarrhythmics, antibiotics, antipsychotic, and antidepressants. It is critical to monitor electrolyte levels, other drugs taken, as well as risks related to the cardiovascular system.

Hepatic problems: Drug reactions may include the impact of drugs on the liver leading to incidents of drug-related injuries, which manifest themselves through asymptomatic enzymes growing leading up to severe liver dysfunction. The severity of the reaction depends on the drug metabolism, immune system reactions, condition of the liver, as well as concurrent medications. Hence, monitoring of liver functioning is critical in the event of liver problems related to the drug.

Neurological effects: Drug may lead to side effects including dizziness, sedation, cognitive dysfunction, movement disorders, etc. To minimize the consequences of the above drug-related consequences, appropriate dosages and some monitoring measures [36].

9.3 Factors Contributing to Medication Safety Risks

Women become susceptible to medication safety risks as a result of multiple factors. The interaction of pharmacokinetic and pharmacodynamics processes, genetics, hormones, and clinical factors leads to different rates of drug metabolism and elimination. Differences in the drug metabolism and elimination patterns ultimately lead to different systemic exposures, where different receptor sensitivity translates into different therapeutic and adverse effects. Other important factors to consider when it comes to medication safety including age, bodyweight, pregnancy, breastfeeding, menopause, kidney or liver diseases, as well as multiple chronic diseases. Polypharmacy increases the likelihood of drug-to-drug interactions, while the influence of pharmacogenomics makes an impact on the way specific medications are processed. Moreover, there is the problem of underrepresentation of women in clinical trials, which influences the availability of proper safety data. Medication mistakes, incorrect dosages, lack of monitoring, and insufficient awareness from patients contribute to the problem even further. Therefore, the comprehensive evaluation of patients' characteristics, medication history, and laboratory data is vital to be able to detect and tackle safety issues [37].

9.4 Strategies for Preventing and Managing Adverse Drug Reactions

To prevent adverse drug reactions, appropriate medication selection should be complemented with dose adjustments and thorough assessment of treatment response. Faculty members must carefully review the patient's medical history, previous allergies, concomitant medications, renal and liver functions, and any important reproductive or hormonal status prior to starting the therapy. The appropriate dose adjustments should be made according to the reliable information regarding prescription practices and individual clinical data. The medications with a possibility of adverse reactions must be monitored by evaluating ECG results, liver function tests, renal functions, or therapeutic drug monitoring. The patients must be informed about the chances of adverse effects and instructed to report any uncommon symptoms to their doctors as soon as possible. If a healthcare provider is concerned about the potential for an adverse

effect, the specialist will evaluate the gravity of the situation, find out the medications that are likely to have caused this reaction, and consider the possibility of dose adjustment, refusal from the recommended treatment, or suggestion of another therapy. All serious suspected adverse reactions must be reported to pharmacovigilance systems to ensure the rapid response to potential risk situations and further elimination of any preventable drug-related damage [38].

10. Pharmacogenomics in Female-Specific Clinical Pharmacology

Pharmacogenomics looks at the role of genes in how people will react to a drug and how well it works, how quickly the body can break down the drug after it has been administered and whether the drug has any side effects. The differences in genes make different people react to the drugs differently; the genes can be involved in encoding enzymes and transporters that break the drugs in the body. In order to make drug use more efficient in women's clinical pharmacology, pharmacogenomics can provide effective ways of personalizing the treatment approach, taking the genetic profile of the patient into account in combination with hormonal state, reproductive capabilities, age, and other aspects [39].

10.1 Genetic Variability in Drug-Metabolizing Enzymes

Genetic changes in genes responsible for drug metabolism may modify the processes of converting drugs to active and inactive forms. Changes in CYP2D6, CYP2C19, CYP2C9, and other similar genes may cause differences in metabolism phenotypes that scientists generally classify as poor metabolizers, intermediates, normal metabolizer, or ultrarapid metabolizer, depending on the metabolic enzyme and the appropriate classification system. Over time, it has been learned that CYP2C19 polymorphisms may affect the clopidogrel activation, while CYP2D6 genetic changes can determine the metabolism of drugs like antidepressants and opioids. CYP2C9 and VKORC1 may cause a certain requirement of the warfarin dose and bleeding risk. Thus, the mentioned cases prove that genetic information could explain the differences between therapeutic responses and their toxic effects. The effects of genetic polymorphisms on drug metabolism are considered to be the same in women and men. However, such effects might depend on physicochemical characteristics [40].

10.2 Gene–Hormone Interactions in Drug Response

The term 'gene-hormone interactions' describes the effect of gene variations along with influence of hormones on processes that take part in drug response. Estrogens and progesterone are hormones that can affect expression of genes and signaling in cells, while variations of the gene can modify behavior of enzymes, transporters and receptors that are important for pharmacological processes. Gene-hormone interactions can be responsible for differences in metabolism of drugs in different periods of the menstrual cycle. It causes variations in the sensitivity of receptors to drugs, as well as the effect of drugs on people having certain gene variants in their genotypes. Thus, hormonal fluctuations during pregnancy may lead to changes in functioning of specific biochemical pathways resulting in various impacts of medications on patients with certain gene characteristics. However, even though there are many potential interactions between genes and hormones, their clinical significance is still unknown and needs additional studies to derive reliable connections and prove that these connections can help select the best drugs and their dosages. Before the scientific problem is solved, practitioners can apply existing recommendations for individualizing drug therapy, as well as use verified pharmacogenomic recommendations [41].

10.3 Pharmacogenomic Applications in Women's Healthcare

Pharmacogenomics leads to advancements in drug selection, administration of drugs, and safety. By examining genes, pharmacogenomics helps find out which patients can benefit from the switch of medication or change in the dosage of certain medications due to their ability to absorb or react to medications differently. Where appropriate, pharmacogenomic tests assist in prescribing antidepressants, antiplatelet drugs, blood thinners, and certain other chemotherapy drugs (**Table 4)**. For example, if a patient's CYP2C19 gene is taken into consideration, that patient can be treated with clopidogrel in proper cardiovascular situations; if the CYP2D6 or CYP2C19 genes are analyzed, an optimal antidepressant can be prescribed to the patient. The use of pharmacogenomics in women's health requires taking into account the various factors that may affect the health of the patient, such as whether the patient is pregnant or breastfeeding. Gene analysis results should be interpreted in accordance with proven guidelines and not independently. As the number of scientific studies supporting the effectiveness of pharmacogenomics as well as the number of pharmacogenomic tests keeps increasing,

integrating pharmacogenomics into clinical practice will help develop precision medicine and prevent adverse drug reactions [42].

Table 4. Pharmacogenomic Factors Influencing Drug Response and Dose Requirements in Women

Gene	Associated drug	Effect of genetic variation	Clinical significance
CYP2D6	Tamoxifen	Reduced enzyme activity can decrease the formation of active metabolites	May influence treatment effectiveness in breast cancer
CYP2C9	Warfarin	Reduced enzyme activity may decrease warfarin metabolism	May require a lower initial dose and careful monitoring
VKORC1	Warfarin	Genetic variations affect sensitivity to warfarin	Helps guide individualized anticoagulant dosing
CYP2C19	Clopidogrel	Reduced enzyme activity decreases formation of its active metabolite	May reduce antiplatelet effectiveness
TPMT	Azathioprine, mercaptopurine	Reduced enzyme activity increases the risk of drug toxicity	Helps identify patients requiring modified treatment
NUDT15	Azathioprine, mercaptopurine	Certain variants increase susceptibility to severe treatment-related toxicity	Supports safer thiopurine dose selection
DPYD	Fluorouracil, capecitabine	Reduced enzyme activity increases the risk of severe toxicity	Helps guide dose reduction or avoidance depending on enzyme activity

11. Precision Dosing

When it comes to precision dosing, selecting the proper dose of drug for each patient is achieved by taking into account several parameters that determine drug exposure, therapeutic response, and possible side effects. Conventional dosing methodologies are based on using standard regimens, but they fail to address necessary variations in different patients' physiological parameters. In women, this aspect is relevant since parameters such as hormonal status, genetic makeup, age, etc. influence the drug requirements significantly [43].

11.1 Factors Influencing Dose Requirements in Women

In order to determine medication dosage requirements in women, several factors must be taken into account. These factors are weight, body composition, age, use of other medications, or genetics. The way drugs spread in the body can vary depending on how much body fat and water a person has, and the way drugs interact with each other and how the body gets rid of medications can also change the effects of a certain medication. Hormonal status can be important for some medications as well during pregnancy, in postpartum period, and during menopause. Due to pregnancy plasma volume changes in metabolism, binding of drugs to protein, and filtration, drugs' actions and effects can change. Moreover, pills and other drugs can provoke certain reactions in the enzymes that break drugs down in the body. Therefore, the selection of the dose of the drug should be based on its recommendation, the condition of the patient, and relevant factors [44].

11.2 Therapeutic Drug Monitoring and Dose Optimization

Therapeutic drug monitoring refers to the measurement of the concentration of a drug in body fluids so as to inform therapy where such measurements are useful. This is especially true for certain drugs having narrow therapeutic index, high variability in pharmacokinetics, and a clear relationship between concentration and outcome of treatment. TDM can help detect subtherapeutic concentrations, overdosing, noncompliance with therapy, and potential drug-drug interactions. Monitoring may consist of different sampling types when the drug being examined varies, including trough concentrations, peak concentrations, etc. The interpretation

of the results should link the time of sampling, dosage schedule, clinical observations, and other laboratory findings. In women, TDM may be helpful when physiologic changes in pregnancy or another clinical situation change the pharmacokinetics of a drug being monitored. The proper way to conduct the drug dosing is using validated therapeutic doses rather than relying on the concentration levels alone [45].

11.3 Physiologically Based Pharmacokinetic Modeling

PBPK modeling is a method that uses physiological, anatomical, and biochemical information to predict the behaviour of drugs in terms of absorption, distribution, metabolism, and excretion. Thus, PBPK modeling takes into account many factors, both physiological, like blood flow and organ size, and drug-specific ones. Moreover, PBPK models can be modified to take into account the differences in physiology between males and females or changes that occur during pregnancy and childbirth. As an illustration, it is possible to create a PBPK model for pregnancy which accounts for such variables as plasma volume and liver enzymes activity. PBPK models can help in case of selecting the correct dosage or checking drug interactions, but their effectiveness depends on the quality of input data and assumptions as well as the data validation for clinical outcomes. Hence, PBPK modeling is a helpful addition to clinical studies, but not a replacement for them [46].

11.4 Evidence-Based Dosing Across Reproductive Life Stages

When prescribing medication to women, accounting for the physiological changes that women undergo throughout the different reproductive life stages is of utmost importance, while still taking evidence-based prescriptive practice into consideration. When it comes to the adolescent stage, the determination of medication dosage may depend on physiological factors, weight, and the medication being given. Pregnancy has the potential to lead to considerable changes in drug distribution, metabolism, and elimination which could, in turn, alter therapeutic needs. It is also essential to understand how drugs will affect the fetus as well as the possible dangers of not treating a woman's condition while she is pregnant. Drug use during lactation should consider when it comes to drugs passing into breast milk as well as the potential impact that this might have on the infant as reasonable conclusions are drawn from individual drugs. Age-related effects, prejudice, and changes in body composition will contribute to women requiring

different medications throughout perimenopause and menopause. Age does not mean that women have to be prescribed different dosages regardless of their situation in life [47].

12. Individualized Pharmacotherapy

Customized pharmacotherapy aims at providing the right medicine and optimal doses for each individual depending on his/her characteristics, physiological status, and clinical requirements. Drug response in women may differ owing to a number of factors, including hormonal changes, genetic features, age, body composition, reproductive health, organ functioning, and medications used simultaneously. Taking these factors into account allows clinicians to prepare personalized treatment plans that are suitable for every patient. The implementation of individualized pharmacotherapy into clinical practice leads to improved treatment effect, lowered risk of drug side effects, and increased safety of medications thus leading to better treatment effect in women of different life stages such as adolescence, pregnancy, and menopause [48].

12.1 Patient-Centered Medication Selection

Choosing patient-centered medications means selecting the right medication based on patient diagnosis and disease severity, and treatment goals, medical history, preventive and possible health risks. In women's health, other factors to consider include menstrual cycle symptoms, pregnancy, lactation, birth control use, and early changes related to menopause. Apart from efficacy, safety, drug contradictions, and drug interactions need to be taken into account in medication selection. For instance, when prescribing medication during pregnancy, careful assessment of benefits to the mother and risks to the fetus is required; and when administering drugs during lactation, the extent of drug transfer to the breast milk and effect on the baby must be taken into consideration. Patient education and patient participation are important aspects of personalized approach in medicine. Informing the patient about various therapeutic possibilities and possible side effects, as well as monitoring plans enables the patient to participate in their treatment [49].

12.2 Integration of Hormonal Status, Genetics, and Clinical Factors

Pharmacotherapy personalized means the need for integrating biochemical, genetic, physiological, and clinical aspects. The hormonal status of an individual can determine some

of the pathways of metabolism, activity of receptors, and the physiological reaction of a body. The reason behind genetic differences is that drugs work via some of the specific enzymes, that metabolize drugs and impact their receptors. Genetic information can be applied to identify patients who should be treated differently. For instance, CYP2C19 polymorphisms have an impact on clopidogrel activation, while CYP2D6 does on some antidepressants and opioids. Therefore, the data should be interpreted according to the established clinical guidelines. Another important factor is taking into account all clinical data related to the patients, such as their age, weight, renal and liver function, stage of a disease, and other medications that are being taken at the same time. The absence of this knowledge about each patient can mislead doctors. The knowledge of the reproductive states, i.e., pregnancy, may allow for changing the treatment approach. When the mentioned factors are combined with clinical evidence, it enables better medication selection [50].

12.3 Personalized Treatment Strategies and Clinical Decision-Making

During personalized therapy, the main objective is to achieve the desired effect with limited toxicity and exposure to unnecessary drugs. In order to make decisions regarding treatment, the doctor should take into account the body characteristics and the response to the therapy of a particular patient, lab results, history of medications used by the patient, and pharmacogenetics background (**Figure 5)**. Therapeutic drug monitoring may help with dosage adjustment of some medications, which possess either narrow therapeutic range or high variability. Similarly, the evaluation of renal and liver functions allows to find the patients who need their doses changed in order to avoid overdose and insufficient exposure to drugs. It is necessary to follow up the therapy in order to assess the response, check for possible side effects, and assess the need for changes in treatment approach. The patient's preferences, compliance, accessibility, and possible drug interactions also have to be taken into account. By mixing clinical thinking with proper monitoring and evidence-based medicine references, doctors can design a therapeutic plan taking into account the needs of women [51].



Figure 5 Individualized Pharmacotherapy and Precision Dosing

12.4 Emerging Approaches in Precision Women's Medicine

Innovation in precision medicine provides new avenues for enhancing pharmacotherapy in women's health. Pharmacogenomic testing, artificial intelligence (AI), physiologically based pharmacokinetic (PBPK) modeling, and digital health technologies can be used to predict response to treatment and identify patients who are more likely to suffer side effects. AI technologies with Decision Support Systems for Clinicians (DSS) enable the integration of patient characteristics, laboratory data, medication history, and genetic information for optimal drug choice and dosing. PBPK modeling allows for forecasting drug exposure in pregnancy and in other physiological transformations while using digital health technologies to promote adherence to treatment. However, as far as clinical utility is concerned, it should be noted that the future of advanced technologies lies in the quality of data, the validation of models, and proper clinical interpretation. For the future developments of such technologies the significance

of adequate clinical datasets, ethical aspects of data usage, and validation of technologies on representative populations of women should be highlighted [52].

13. Current Challenges and Future Perspectives

Despite advancements in pharmacology and personalized medicine, issues regarding gender differences in drug response continue to exist. Women have historically been left out of clinical trials, and resources, such as data on women's responses to treatment as well as proper evidence-based dosing, have not been utilized properly. In addition to this, methods of administering the treatment should include the issues of hormonal changes, reproductive condition, and modifications to human physiology. In order to solve the problem with gender treatment responses, inclusivity in research and the techniques of data collection should be improved [53].

13.1 Challenges in Sex-Specific Drug Research

One of the biggest problems in research of drugs based on sex is the historic lack of women in certain clinical trials. Despite improvements in the participation of females in research, still the clinical studies do not collect enough evidence and data to define gender-based differences in drug absorption, efficiency and side effects. Fluctuations in hormones, pregnancy, breastfeeding etc. complicate the process of drug effectiveness evaluation. Specific features of trial design, as well as characteristics of participants and measurement of hormonal status all lead to some difficulties when evaluating results obtained in various studies. Besides, sex can interact with many factors such as age, genetic characteristics, environment and diseases, which makes it difficult to analyze the results obtained in different studies. In order to improve the situation, it is important to make sure females are adequately represented, that the analysis of results is performed in an appropriate way, and that the results of studies can be treated according to the principle of well-designed studies and real-life evidence [54].

13.2 Limitations in Female-Specific Dosing Guidelines

Despite the fact that there have been recorded sex-specific differences in pharmacodynamics and pharmacokinetics of some drugs, there is still not enough evidence to provide sex-specific recommendations for dosing of drugs. Typically, established recommendations for dosing are made based on clinical studies, which often fail to take into account the impact of hormones

on the studied processes and the changes occurring across different periods in the initiation of reproductive life. Another limitation is that it is hard to distinguish the impact of biological sex, body weight, organ capacity, genetic parameters, concomitant treatment, and diseases on the studied processes. It is undeniable that hormones could affect some processes of pharmacodynamics or pharmacokinetics; but there is no general rule for all drugs. Therefore, making dose adjustments based on menstrual cycle phase or hormonal status could hardly be justified without additional evidence. Improving dosing recommendations would require carrying out pharmacokinetic studies of specific drugs, carrying out studies with sufficient power, and evaluating adverse effects systematically [55].

13.3 Future Directions in Precision Pharmacotherapy

The future studies should focus on merging sex-based pharmaceuticals with pharmacogenomics, drug monitoring, and computational modeling. Such mechanisms can help physicians to determine patients who are more likely to gain from specific medications or in need of more scrupulous monitoring due to changes in drug exposure or greater risk of adverse effects. PBPK models and AI-assisted decision-making provide new possibilities for information related to drug absorption in various physiological situations such as pregnancy and other states concerning reproduction. However, the aforementioned instruments need to be validated on good quality clinical data and population before use on a wide scale. Clinical studies in the future should be conducted with the sufficient number of women and with studying the effectiveness of treatment in different age groups and ages of reproductive life. More collaboration between clinical pharmacologists, clinical pharmacists, doctors, scientists, and authorities may allow translating the findings of research into the practice of prescription. In the end, the precision therapy should take into account the biological sex and hormonal status, genetic polymorphism, characteristics, and preferences of the patient [56].

14. Conclusion

Female pharmacology is an essential part of medicine; its function is to observe how physiological variables, hormonal changes, heredity, and stages of reproduction affect the way drugs act in the human body. Different methods of drug absorption, distribution, metabolism, and elimination and their ways in opposition to how the drug works can explain the difference

in effectiveness of treatment and the occurrence of side effects. Thus, it is important to understand those factors if one wants to provide better care for women.

Hormonal changes influenced by the menstrual cycle, pregnancy, lactation, and menopause can have an influence on a number of pharmacological processes, although the significance of this influence is different for different drugs. The same is true about differences between men and women as far as the activity of cytochrome P450, drug carriers, sensitivity of receptors, etc. Therefore, it is vital to find specific proof about every drug instead of applying some general rules while determining dosing amounts by relying upon biological sex solely.

Progress in pharmacogenomics, therapeutic drug monitoring, physiologically based pharmacokinetic dating, and artificial intelligence presents new opportunities for personalized pharmacotherapy. However, more research is needed to bridge the gap in female-specific clinical evidence, increase female representation in trials, and develop guidelines for drug dosage recommendations in different vital stages. Using sex-specific research results and clinical indicators together with the patients' preferences can enhance the safety and efficacy of the drugs used. Ultimately, development of female-centered clinical pharmacology contributes to evidence-based prescription decisions, personalized treatment approaches, and better patient outcomes.

References

1. Romanescu M, Buda V, Lombrea A, Andor M, Ledeti I, Suciu M, Danciu C, Dehelean CA, Dehelean L. Sex-related differences in pharmacological response to CNS drugs: a narrative review. Journal of Personalized Medicine. 2022 May 31;12(6):907.
2. Campesi I, Capobianco G, Virdis G, Franconi F. Understanding pharmacokinetic variability in women across different life stages. Expert Opinion on Drug Metabolism & Toxicology. 2026 May 4;22(5):335-56.
3. de Beer F, Brand BA, Wijnen B, Gangadin SS, Schoretsanitis G, Touw D, Sommer IE, PHAMOUS investigators Castelein Stynke Jörg Frederike Liemburg Edith van der Meer Lisette Pijnenborg Gerdina HM Veling Wim Visser Ellen de Vos Sander. The impact of sex and age on antipsychotic serum concentrations. Schizophrenia Bulletin. 2026 Mar;52(2):sbaf217.

4. Colpani A, De Vito A, Russo A, Geremia N, Giacomelli A, Marino A, Trunfio M, Scaglione V, Maraolo AE, Mazzitelli M. Impact of sex and gender medicine on antibiotic research and use: a narrative review of existing evidence. Expert Opinion on Drug Metabolism & Toxicology. 2026 Jan 2;22(1):39-56.
5. Arterburn JB, Prossnitz ER. G protein–coupled estrogen receptor GPER: molecular pharmacology and therapeutic applications. Annual review of pharmacology and toxicology. 2023 Jan 20;63(1):295-320.
6. Petrie KA, Burbank K, Sizer PS, James CR, Zumwalt M. Considerations of sex differences in musculoskeletal anatomy between males and females. InThe active female: health issues throughout the lifespan 2023 Feb 26 (pp. 3-24). Cham: Springer International Publishing.
7. Athar F, Karmani M, Templeman NM. Metabolic hormones are integral regulators of female reproductive health and function. Bioscience reports. 2024 Jan;44(1):BSR20231916.
8. Aljohmani A, Yildiz D. Biological sex differences in pharmacokinetics and adverse drug reactions. Naunyn-Schmiedeberg's archives of pharmacology. 2026 Feb;399(3):3285-301.
9. Chakraborty B, Byemerwa J, Krebs T, Lim F, Chang CY, McDonnell DP. Estrogen receptor signaling in the immune system. Endocrine reviews. 2023 Feb 1;44(1):117-41.
10. Bosch EL, Sommer IE, Touw DJ. The influence of female sex and estrogens on drug pharmacokinetics: what is the evidence?. Expert Opinion on Drug Metabolism & Toxicology. 2025 Jun 3;21(6):637-47.
11. Ahmed R, Zyla S, Hammond N, Blum K, Thanos PK. The role of estrogen signaling and exercise in drug abuse: a review. Clinics and Practice. 2024 Jan 8;14(1):148-63.
12. Yu Z, Jiao Y, Zhao Y, Gu W. Level of estrogen in females—the different impacts at different life stages. Journal of Personalized Medicine. 2022 Dec 2;12(12):1995.
13. Weatherly S, Garazi CD, Woldenberg E, Ravigopal T, Costin J. Unraveling the Cycle: A Scoping Review Exploring the Impact of Antidepressants on the Female Reproductive Cycle. Cureus. 2025 Nov 20;17(11).

14. Dole A, Beaven M, Sims ST. Menstrual cycle tracking in sports research: challenges, progress, and future directions. Physiologia. 2023 Nov 24;3(4):598-610.
15. Yoon S. Pharmacokinetics/pharmacodynamics and sex differences. InSex/gender-specific medicine in clinical areas 2024 Jun 4 (pp. 541-552). Singapore: Springer Nature Singapore.
16. Thakur A, Yue G, Ahire D, Mettu VS, Al Maghribi A, Ford K, Peixoto L, Leeder JS, Prasad B. Sex and the Kidney Drug-Metabolizing Enzymes and Transporters: Are Preclinical Drug Disposition Data Translatable to Humans?. Clinical Pharmacology & Therapeutics. 2024 Jul;116(1):235-46.
17. Haduch A, Danek PJ, Kuban W, Pukło R, Alenina N, Gołębiowska J, Popik P, Bader M, Daniel WA. Cytochrome P450 2D (CYP2D) enzyme dysfunction associated with aging and serotonin deficiency in the brain and liver of female Dark Agouti rats. Neurochemistry international. 2022 Jan 1;152:105223.
18. Kasarinaite A, Sinton M, Saunders PT, Hay DC. The influence of sex hormones in liver function and disease. Cells. 2023 Jun 11;12(12):1604.
19. Avila M, Mora Sánchez MG, Bernal Amador AS, Paniagua R. The metabolism of creatinine and its usefulness to evaluate kidney function and body composition in clinical practice. Biomolecules. 2025 Jan 1;15(1):41.
20. Natalucci V, Spinello G, Moro T, Pavei G, Boccia G, La Torre A, Bonato M. Menstrual Cycle and Hormonal Contraceptives in Female Athletes: Should Symptoms and Nutrition Matter More than Cycle Phase? A Narrative Review. Nutrients. 2026 Apr 2;18(7):1144.
21. Le A, Valicherla GR, Zhang J, Wang L, Donnelly MK, Bies R, Rohan LC. Expanding the Gene Expression Profiling of Drug Transporters and Drug-Metabolizing Enzymes to Include the Upper Female Reproductive Tract. Pharmaceutics. 2026 May 21;18(5):629.
22. Hossam Abdelmonem B, Abdelaal NM, Anwer EK, Rashwan AA, Hussein MA, Ahmed YF, Khashana R, Hanna MM, Abdelnaser A. Decoding the role of CYP450 enzymes in

metabolism and disease: a comprehensive review. Biomedicines. 2024 Jul 2;12(7):1467.

23. Helal SA, Gerges SH, El-Kadi AO. Sex-Specific Differences in Rat Renal CYP Enzyme Expression and Activity Following Isoproterenol-Induced Injury: SA Helal et al. European Journal of Drug Metabolism and Pharmacokinetics. 2026 Jan;51(1):111-26.
24. Kamran SH, Rehman K, Akash MS, Khan A, Laher I. Impact of physiological factors on drug-metabolizing enzymes: From function to regulation. InBiochemistry of drug metabolizing enzymes 2022 Jan 1 (pp. 281-304). Academic Press.
25. Koo N, Lee EJ, Chang JE, Lee KR, Chae YJ. Pharmacokinetic Landscape and Interaction Potential of SGLT2 Inhibitors: Bridging In Vitro Findings and Clinical Implications. Pharmaceutics. 2025 Dec 12;17(12):1604.
26. Galetin A, Brouwer KL, Tweedie D, Yoshida K, Sjöstedt N, Aleksunes L, Chu X, Evers R, Hafey MJ, Lai Y, Matsson P. Membrane transporters in drug development and as determinants of precision medicine. Nature reviews Drug discovery. 2024 Apr;23(4):255-80.
27. Mineiro R, Santos C, Gonçalves I, Lemos M, Cavaco JE, Quintela T. Regulation of ABC transporters by sex steroids may explain differences in drug resistance between sexes: Mineiro et al. Journal of physiology and biochemistry. 2023 Aug;79(3):467-87.
28. Gong C, Bertagnolli LN, Boulton DW, Coppola P. A literature review of changes in phase II drug-metabolizing enzyme and drug transporter expression during pregnancy. Pharmaceutics. 2023 Nov 15;15(11):2624.
29. Patel A, Patel R. Pharmacokinetics and drug disposition: the role of physiological and biochemical factors in drug absorption and elimination. Journal of Applied Optics. 2023 Jun 30;44(1):48-67.
30. Mortberg MA, Zhao HT, Reidenbach AG, Gentile JE, Kuhn E, O'Moore J, Dooley PM, Connors TR, Mazur C, Allen SW, Trombetta BA. Regional variability and genotypic and pharmacodynamic effects on PrP concentration in the CNS. JCI insight. 2022 Mar 22;7(6):e156532.

31. Wu X, Chen L, Chen Y, Liu Y, Chen X. Sex differences in chemotherapy-induced neuropathic pain: mechanisms and pharmacotherapy. Journal of Pharmacy and Pharmacology. 2026 Mar;78(3):rgag025.
32. Xia W, Khalil RA. Hormone replacement therapy and cardiovascular health in postmenopausal women. International Journal of Molecular Sciences. 2025 May 24;26(11):5078.
33. Kouzkouz N, Mallard J, Hucteau E, Schott R, Pivot X, Ducrocq GP, Hureau TJ. Innovative Dose–Response Assessment of the Metaboreflex With Indirect Control of Intramuscular Metabolic Perturbation in Humans. Acta Physiologica. 2026 Oct;242(10):e70303.
34. Brabete AC, Greaves L, Maximos M, Huber E, Li A, Lê ML. A sex-and gender-based analysis of adverse drug reactions: a scoping review of pharmacovigilance databases. Pharmaceuticals. 2022 Feb 28;15(3):298.
35. Adil M, Iqbal M, Kanwal S, Abbas G. Toxicity and adverse effects of veterinary pharmaceuticals in animals. InPharmaceuticals in aquatic environments 2023 Aug 28 (pp. 141-159). CRC Press.
36. Gao W, Guo L, Yang Y, Wang Y, Xia S, Gong H, Zhang BK, Yan M. Dissecting the crosstalk between Nrf2 and NF-κB response pathways in drug-induced toxicity. Frontiers in cell and developmental biology. 2022 Feb 2;9:809952.
37. Alqenae FA, Steinke D, Carson-Stevens A, Keers RN. Analysis of the nature and contributory factors of medication safety incidents following hospital discharge using National Reporting and Learning System (NRLS) data from England and Wales: a multi-method study. Therapeutic advances in drug safety. 2023 Mar;14:20420986231154365.
38. Lacroix C, Maurier A, Largeau B, Destere A, Thillard EM, Drici M, Micallef J, Jonville-Bera AP. Sex differences in adverse drug reactions: Are women more impacted?. Therapies. 2023 Mar 1;78(2):175-88.

39. Türkmen D, Masoli JA, Kuo CL, Bowden J, Melzer D, Pilling LC. Statin treatment effectiveness and the SLCO1B1* 5 reduced function genotype: Long-term outcomes in women and men. British journal of clinical pharmacology. 2022 Jul;88(7):3230-40.
40. McCoy M. Multi-tissue Analysis of ADME Gene Expression: Sex and Age Effects Across Human Organ Systems. Drug Metabolism and Disposition. 2025 Sep 11:100162.
41. Fisher JL, Clark AD, Jones EF, Lasseigne BN. Sex-biased gene expression and gene-regulatory networks of sex-biased adverse event drug targets and drug metabolism genes. BMC Pharmacology and Toxicology. 2024 Jan 2;25(1):5.
42. Enitan S, Adejumo E, Imaralu J, Adelakun A, Ladipo O, Enitan C. Personalized medicine approach to osteoporosis management in women: integrating genetics, pharmacogenomics, and precision treatments. Clin Res Commun. 2023;6(3):18.
43. Özdemir BC, Gerard CL, Espinosa da Silva C. Sex and gender differences in anticancer treatment toxicity: a call for revisiting drug dosing in oncology. Endocrinology. 2022 Jun 1;163(6):bqac058.
44. Devi M, Shajan SR, Walikar S, Honnasiddappa DB, Sajjan M, Ammunje DN. 7. FACTORS INFLUENCING DOSE CALCULATIONS. PHARMACOLOGICAL ESSENTIALS: A PRACTICAL GUIDE TO DRUG DOSING, INTERACTIONS, AND SAFE MEDICATION PRACTICES.:103.
45. de Lima Moreira F, de Lima Benzi JR, Pinto L, de Lucca Thomaz M, Duarte G, Lanchote VL. Optimizing therapeutic drug monitoring in pregnant women: a critical literature review. Therapeutic drug monit
46. Adams K, Li X, Rohan L, Bies R. PBPK models of the female reproductive tract: current and future analysis. Expert Opinion on Drug Metabolism & Toxicology. 2025 Apr 3;21(4):429-44.
47. Wyckoff JA, Lapolla A, Asias-Dinh BD, Barbour LA, Brown FM, Catalano PM, Corcoy R, Di Renzo GC, Drobycki N, Kautzky-Willer A, Murad MH. Preexisting diabetes and pregnancy: an Endocrine Society and European Society of Endocrinology

joint clinical practice guideline. The Journal of Clinical Endocrinology & Metabolism. 2025 Sep;110(9):2405-52.

48. Salatin S, Shafiee-Kandjani AR, Hamidi S, Amirfiroozi A, Kalejahi P. Individualized psychiatric care: integration of therapeutic drug monitoring, pharmacogenomics, and biomarkers. Personalized Medicine. 2025 Jan 2;22(1):29-44.
49. Wang LJ, Wang YJ, Cheng YL, Fang WL, Wang W, Zheng MC. Digital Patient Decision Aid for Antiobesity Medications: Mixed Methods Study of Human-Centered Design and Usability Evaluation. Journal of Medical Internet Research. 2026 May 15;28:e89428.
50. Alsuwaidi A, AlAnouti F, Papandreou D. Endocrine roles of vitamin D in female reproduction: Mechanisms and clinical implications. Women's Health. 2026 Apr;22:17455057261446942.
51. Rajendran OK. Digital Twin Frameworks For Personalized Cancer Progression Modeling Using Longitudinal Data. Power System Protection and Control. 2025 Dec 25;53(4):486-501.
52. Dakhil ZA, Gitti SA, Kaddoura R. Cardiovascular risk prediction in women: rethinking traditional approaches through precision medicine. Frontiers in Global Women's Health. 2026 Feb 20;7:1659244.
53. Nguyen TH, Nguyen HA, Thi YV, Nguyen HT, Cao A, Do QL, Bui TT, Chu DT, Cao H. Emerging Bioengineering Technologies in Female Reproduction: Preclinical Advances, Translational Challenges, and Future Outlook. Biotechnology Journal. 2026 Jul;21(7):e70274.
54. Greaves L, Brabete AC, Maximos M, Huber E, Li A, Lê ML, Eltonsy S, Boscoe M. Sex, gender, and the regulation of prescription drugs: omissions and opportunities. International Journal of Environmental Research and Public Health. 2023 Feb 8;20(4):2962.
55. Puntarello M, Albano GD, Zerbo S, Malta G, Argo A. Sex Differences in Psychotropic Drug Exposure and Safety: A Systematic Review Toward Personalized Dosing Strategies. Journal of Personalized Medicine. 2026 Mar 31;16(4):189.

56. Guo ZQ. Precision pharmacology in menopause: advances, challenges, and future innovations for personalized management. Frontiers in Reproductive Health. 2025 Nov 13; 7:1694240.